Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review

被引：27

作者：

Diedhiou, Demba ^{[1
,2
]}

Cuny, Thomas ^{[1
]}

Sarr, Anna ^{[2
]}

Diop, Said Norou ^{[2
]}

Klein, Marc ^{[1
]}

Weryha, Georges ^{[1
]}

机构：

[1] Lorraine Univ, Univ Hosp Ctr Nancy, Dept Endocrinol, Vandoeuvre Les Nancy, France

[2] Cheikh Anta Diop Univ, Univ Hosp Ctr Dakar, Dept Internal Med 2, Dakar, Senegal

来源：

ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷 / 06期

关键词：

Osteoporosis; Denosumab; Fracture risk; Renal insufficiency; Safety; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; TURNOVER MARKERS; RISK REDUCTION; FRACTURE RISK; ALENDRONATE; THERAPY; MASS; PHASE-2;

D O I：

10.1016/j.ando.2015.10.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6 months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6 months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate. (C) 2015 Elsevier Masson SAS. All rights reserved.

引用

页码：650 / 657

页数：8

共 50 条

[1] Comparative Effect of Zoledronic Acid Versus Denosumab on Serum Sclerostin and Dickkopf-1 Levels of Naive Postmenopausal Women With Low Bone Mass: A Randomized, Head-to-Head Clinical Trial [J].

Anastasilakis, Athanasios D. ;

Polyzos, Stergios A. ;

Gkiomisi, Athina ;

Bisbinas, Ilias ;

Gerou, Spyridon ;

Makras, Polyzois .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (08) :3206-3212

[2] Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures [J].

Austin, Matthew ;

Yang, Yu-Ching ;

Vittinghoff, Eric ;

Adami, Silvano ;

Boonen, Steven ;

Bauer, Douglas C. ;

Bianchi, Gerolamo ;

Bolognese, Michael A. ;

Christiansen, Claus ;

Eastell, Richard ;

Grauer, Andreas ;

Hawkins, Federico ;

Kendler, David L. ;

Oliveri, Beatriz ;

McClung, Michael R. ;

Reid, Ian R. ;

Siris, Ethel S. ;

Zanchetta, Jose ;

Zerbini, Cristiano A. F. ;

Libanati, Cesar ;

Cummings, Steven R. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2012, 27 (03) :687-693

[3]

Beck TJ, 2008, J CLIN DENSITOM, V11, P351, DOI [10.1016/j.jocd.2008.04.001, 10.1016/j.jocd.2007.12.017]

[4] A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women [J].

Bekker, PJ ;

Holloway, DL ;

Rasmussen, AS ;

Murphy, R ;

Martin, SW ;

Leese, PT ;

Holmes, GB ;

Dunstan, CR ;

DePaoli, AM .

JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (07) :1059-1066

[5] Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study [J].

Bolognese, Michael A. ;

Teglbjaerg, Christence Stubbe ;

Zanchetta, Jose R. ;

Lippuner, Kurt ;

McClung, Michael R. ;

Brandi, Maria Luisa ;

Hoiseth, Arne ;

Lakatos, Peter ;

Moffett, Alfred H. ;

Lorenc, Roman S. ;

Wang, Andrea ;

Libanati, Cesar .

JOURNAL OF CLINICAL DENSITOMETRY, 2013, 16 (02) :147-153

[6] Effects of denosumab on bone mineral density and bone turnover in postmenopausal women [J].

Bone, Henry G. ;

Bolognese, Michael A. ;

Yuen, Chui Kin ;

Kendler, David L. ;

Wang, Huei ;

Liu, Yu ;

Martin, Javier San .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (06) :2149-2157

[7] The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension [J].

Bone, Henry G. ;

Chapurlat, Roland ;

Brandi, Maria-Luisa ;

Brown, Jacques P. ;

Czerwinski, Edward ;

Krieg, Marc-Antoine ;

Mellstrom, Dan ;

Radominski, Sebastiao C. ;

Reginster, Jean-Yves ;

Resch, Heinrich ;

Roman Ivorra, Jose A. ;

Roux, Christian ;

Vittinghoff, Eric ;

Daizadeh, Nadia S. ;

Wang, Andrea ;

Bradley, Michelle N. ;

Franchimont, Nathalie ;

Geller, Michelle L. ;

Wagman, Rachel B. ;

Cummings, Steven R. ;

Papapoulos, Socrates .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (11) :4483-4492

[8] Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass [J].

Bone, Henry G. ;

Bolognese, Michael A. ;

Yuen, Chui Kin ;

Kendler, David L. ;

Miller, Paul D. ;

Yang, Yu-Ching ;

Grazette, Luanda ;

San Martin, Javier ;

Gallagher, J. Christopher .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :972-980

[9] Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].

Bone, HG ;

Hosking, D ;

Devogelaer, J ;

Tucci, JR ;

Emkey, RD ;

Tonino, RP ;

Rodriguez-Portales, JA ;

Downs, RW ;

Gupta, J ;

Santora, AC ;

Liberman, UA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199

[10] Treatment with Denosumab Reduces the Incidence of New Vertebral and Hip Fractures in Postmenopausal Women at High Risk [J].

Boonen, S. ;

Adachi, J. D. ;

Man, Z. ;

Cummings, S. R. ;

Lippuner, K. ;

Torring, O. ;

Gallagher, J. C. ;

Farrerons, J. ;

Wang, A. ;

Franchimont, N. ;

San Martin, J. ;

Grauer, A. ;

McClung, M. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (06) :1727-1736

← 1 2 3 4 5 →